Akebia Therapeutics
AKBA
124 hedge funds and large institutions have $58.3M invested in Akebia Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 43 reducing their positions, and 26 closing their positions.
65% more call options, than puts
Call options by funds: $4.35M | Put options by funds: $2.64M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 43
7% less funds holding
Funds holding: 133 → 124 (-9)
10.52% less ownership
Funds ownership: 55.34% → 44.82% (-11%)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
73% less capital invested
Capital invested by funds: $218M → $58.3M (-$160M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.5M |
| 2 |
Millennium Management
New York
|
+$1.51M |
| 3 |
Renaissance Technologies
New York
|
+$814K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$721K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$614K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$10.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$10.1M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.04M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.75M |
| 5 |
Goldman Sachs
New York
|
-$2.67M |
AKBA Hedge Fund Activity: Q1 2022 in Review
124 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2022, worth a combined $58.3M — down 73% from $218M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of AKBA and 17 opened new positions — a net loss of 9 holders — while 43 trimmed existing stakes and 40 added.
The largest buyer was Vanguard Group, adding an estimated $2.5M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $10.5M sold.
- 124 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2022, down from 133 in Q4 2021.
- Funds reported $58.3M of Akebia Therapeutics stock for Q1 2022, down 73% quarter-over-quarter.
- 17 funds opened new Akebia Therapeutics positions in Q1 2022 and 26 closed out, a net change of -9 holders.
- The largest Akebia Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $2.5M added.
- The largest Akebia Therapeutics seller in Q1 2022 was Nantahala Capital Management, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2022.